The user started at a dosage of 0.5 mg/week, increasing it gradually until reaching a maximum dose of 2.5 mg, which they sustained for the last 6 months of their cycle
At the time of writing, retatrutide has not received marketing authorisation from the MHRA or the EMA, and therefore does not have an approved Summary of Product Characteristics (SmPC) or Patient Information Leaflet (PIL) in the UK
The NHS and NICE do not recommend peptides for ED, instead advocating proven treatments like PDE5 inhibitors (sildenafil, tadalafil)
Selection should rest on clinical evaluation, not dosage assumptions
It waits, waits, waits, then hits